Expert Interview
Discussing the top line results of Cellectar's CLOVER WaM of Iopofosine I-131 in Waldenstrom Macroglobulinemia
Ticker(s): CLRBInstitution: University of Athens
- Professor of Hematology and Director of Stem Cell Transplantation Unit in the University of Athens
- Manages more than 30 patients with Waldenstrom macroglobulinemia
- Main research interest is the biology and management of bone disease in multiple myeloma.
Hi Doctor you were early in predicting Iopofosine 131 would be highly efficacious, given and the Clover dataset recently release, how do you feel about this study now both efficacy and toxicity?
Please describe what the typical failed 3rd line WM patient looks like under current standard of care, and compare to what you think Iopofosine131 would look like if given the drug.
Assuming Iopofosine 131 is approved do you think oncologist will move rapidly towards this new treatment paradigm?
Given the data set released on Jan 8th, and maybe making the assumption the data continues to improve, what do you think the likelihood is for Iopofosine 131 to eventually make it to 2nd/1st line?
Do you think the Cellectar should be moving rapidly towards any other indications, and if so which ones?
How would you compare Iopofosine storage/administration logistics with Azedra (iobenguane I-131) that’s being discontinued due to apparent administration logistics issue ?
how much larger is the 2nd line than 3rd line? what does that do to the total US population of potential candidates ?
what do you think of 131 for gliomas' in light of yesterday news on cns clearance ?
Added By: user94fc7f9cAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.